Current progress in human epidermal growth factor receptor 2 targeted therapies in esophagogastric cancer Journal Article
| Authors: | Janjigian, Y. Y.; Braghiroli, M. I. |
| Article Title: | Current progress in human epidermal growth factor receptor 2 targeted therapies in esophagogastric cancer |
| Abstract: | Esophagogastric cancer is a worldwide health problem. The addition of the epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab to chemotherapy increased the overall survival of patients with metastatic HER2-positive esophagogastric cancer. This article discusses the available data to support HER2 as validated biomarker and recently completed and ongoing clinical trials of HER2-directed agents in metastatic and localized disease. Also reviewed is the mechanisms of resistance for HER2-directed therapy and ongoing research strategies including new imaging techniques and studies with patient-derived xenografts. © 2016 Elsevier Inc. |
| Keywords: | targeted therapy; trastuzumab; lapatinib; her2; pertuzumab; esophagogastric cancer; tdm-1 |
| Journal Title: | Surgical Oncology Clinics of North America |
| Volume: | 26 |
| Issue: | 2 |
| ISSN: | 1055-3207 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-04-01 |
| Start Page: | 313 |
| End Page: | 324 |
| Language: | English |
| DOI: | 10.1016/j.soc.2016.10.005 |
| PROVIDER: | scopus |
| PUBMED: | 28279471 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 4 April 2017 -- Source: Scopus |
